Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention 09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frederick, L.
Right arrow Articles by James, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frederick, L.
Right arrow Articles by James, C. D.
[Cancer Research 60, 1383-1387, March 1, 2000]
© 2000 American Association for Cancer Research

Molecular Biology and Genetics

Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas1

Lori Frederick, Xiao-Yang Wang, Greg Eley and C. David James2

Department of Laboratory Medicine and Pathology [L. F., X-Y. W., C. D. J.] and Tumor Biology Program [G. E., C. D. J.], Mayo Clinic and Foundation, Rochester, Minnesota 55905

Several types of epidermal growth factor receptor (EGFR) gene mutations have been reported in glioblastomas, and in nearly all cases the alterations have been reported in tumors with EGFR amplification. The objectives of this study were to determine the frequency and diversity of EGFR mutations in glioblastomas and to determine whether gene mutation is inevitably associated with increased EGFR gene dosage. To accomplish these aims, we sequenced cDNA products representing the entire EGFR coding region in 44 glioblastomas, half of which had EGFR amplification. Coding sequence alterations were identified in 17 of the tumors, and each of these cases had amplified EGFR. No mutations were identified in the 22 tumors without EGFR amplification. An additional 26 glioblastomas with EGFR amplification were then examined to establish more reliable frequencies for each type of mutation identified in the tumors for which the entire gene was sequenced. Transcripts associated with the most common mutation lacked coding sequence for amino acids 6–273 (67%). This mutation has been described extensively in the literature. Transcripts encoding receptors that would truncate at amino acid 958 and transcripts encoding receptors that would lack amino acids 521–603 were the next most common types of alteration. Each of these were observed in 15% of the tumors with EGFR amplification. Other mutations were observed at lower frequencies, but among these were three cases with missense mutations. Sixteen of the 48 tumors with EGFR amplification showed multiple types of EGFR mutations (33%), and in one case it was determined that multiple alterations had occurred in the same transcript. In total, these data are consistent with EGFR mutation being exclusively and frequently associated with EGFR amplification. Furthermore, the determination of multiple EGFR mutations within individual tumors suggests that glioblastomas with EGFR amplification have the capacity to produce a variety of functionally distinct EGFRs.




This article has been cited by other articles:


Home page
 ScienceHome page
D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Science, September 26, 2008; 321(5897): 1807 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
L. Bryan, B. S. Paugh, D. Kapitonov, K. M. Wilczynska, S. M. Alvarez, S. K. Singh, S. Milstien, S. Spiegel, and T. Kordula
Sphingosine-1-Phosphate and Interleukin-1 Independently Regulate Plasminogen Activator Inhibitor-1 and Urokinase-Type Plasminogen Activator Receptor Expression in Glioblastoma Cells: Implications for Invasiveness
Mol. Cancer Res., September 1, 2008; 6(9): 1469 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Martens, Y. Laabs, H. S. Gunther, D. Kemming, Z. Zhu, L. Witte, C. Hagel, M. Westphal, and K. Lamszus
Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2
Clin. Cancer Res., September 1, 2008; 14(17): 5447 - 5458.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. Scaltriti and J. Baselga
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 91 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res., February 15, 2008; 14(4): 957 - 960.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
B. S. Paugh, S. W. Paugh, L. Bryan, D. Kapitonov, K. M. Wilczynska, S. M. Gopalan, H. Rokita, S. Milstien, S. Spiegel, and T. Kordula
EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKC{delta}, and sphingosine kinase 1 in glioblastoma cells
FASEB J, February 1, 2008; 22(2): 455 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Yang, G. Wu, R. F. Barth, M. R. Swindall, A. K. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. J. Sferra, P. J. Binns, et al.
Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies
Clin. Cancer Res., February 1, 2008; 14(3): 883 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yoshimoto, J. Dang, S. Zhu, D. Nathanson, T. Huang, R. Dumont, D. B. Seligson, W. H. Yong, Z. Xiong, N. Rao, et al.
Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples
Clin. Cancer Res., January 15, 2008; 14(2): 488 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Dev., November 1, 2007; 21(21): 2683 - 2710.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lu, X. Li, K. Liang, R. Luwor, Z. H. Siddik, G. B. Mills, J. Mendelsohn, and Z. Fan
Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab
Cancer Res., September 1, 2007; 67(17): 8240 - 8247.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. French, J. Peeters, S. Horsman, E. Duijm, I. Siccama, M. J. van den Bent, T. M. Luider, J. M. Kros, P. van der Spek, and P. A. Sillevis Smitt
Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays
Cancer Res., June 15, 2007; 67(12): 5635 - 5642.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari
The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization
Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. N. Sarkaria, L. Yang, P. T. Grogan, G. J. Kitange, B. L. Carlson, M. A. Schroeder, E. Galanis, C. Giannini, W. Wu, E. B. Dinca, et al.
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Mol. Cancer Ther., March 1, 2007; 6(3): 1167 - 1174.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Wu, W. Yang, R. F. Barth, S. Kawabata, M. Swindall, A. K. Bandyopadhyaya, W. Tjarks, B. Khorsandi, T. E. Blue, A. K. Ferketich, et al.
Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab
Clin. Cancer Res., February 15, 2007; 13(4): 1260 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. K. Gan, F. Walker, A. W. Burgess, A. Rigopoulos, A. M. Scott, and T. G. Johns
The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers: IMPLICATIONS FOR COMBINATION THERAPY WITH MONOCLONAL ANTIBODY 806
J. Biol. Chem., February 2, 2007; 282(5): 2840 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Allen, S. Vongpunsawad, T. Nakamura, C. D. James, M. Schroeder, R. Cattaneo, C. Giannini, J. Krempski, K.-W. Peng, J. M. Goble, et al.
Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity
Cancer Res., December 15, 2006; 66(24): 11840 - 11850.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Nicholas, R. V. Lukas, N. F. Jafri, L. Faoro, and R. Salgia
Epidermal Growth Factor Receptor-Mediated Signal Transduction in the Development and Therapy of Gliomas
Clin. Cancer Res., December 15, 2006; 12(24): 7261 - 7270.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Scaltriti and J. Baselga
The epidermal growth factor receptor pathway: a model for targeted therapy.
Clin. Cancer Res., September 15, 2006; 12(18): 5268 - 5272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al.
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Yang, R. F. Barth, G. Wu, S. Kawabata, T. J. Sferra, A. K. Bandyopadhyaya, W. Tjarks, A. K. Ferketich, M. L. Moeschberger, P. J. Binns, et al.
Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4.
Clin. Cancer Res., June 15, 2006; 12(12): 3792 - 3802.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, et al.
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
PNAS, May 16, 2006; 103(20): 7817 - 7822.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. B. Ramnarain, S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, et al.
Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Cancer Res., January 15, 2006; 66(2): 867 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al.
ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H.Y. Huang, D. J. Chute, et al.
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors.
N. Engl. J. Med., November 10, 2005; 353(19): 2012 - 2024.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Lassman, M. R. Rossi, J. R. Razier, L. E. Abrey, F. S. Lieberman, C. N. Grefe, K. Lamborn, W. Pao, A. H. Shih, J. G. Kuhn, et al.
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
Clin. Cancer Res., November 1, 2005; 11(21): 7841 - 7850.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Perera, Y. Narita, F. B. Furnari, H. K. Gan, C. Murone, M. Ahlkvist, R. B. Luwor, A. W. Burgess, E. Stockert, A. A. Jungbluth, et al.
Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity
Clin. Cancer Res., September 1, 2005; 11(17): 6390 - 6399.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. S. Krause and R. A. Van Etten
Tyrosine Kinases as Targets for Cancer Therapy
N. Engl. J. Med., July 14, 2005; 353(2): 172 - 187.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Cappuzzo, F. R. Hirsch, E. Rossi, S. Bartolini, G. L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, et al.
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small-Cell Lung Cancer
J Natl Cancer Inst, May 4, 2005; 97(9): 643 - 655.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
B. Kaur, F. W. Khwaja, E. A. Severson, S. L. Matheny, D. J. Brat, and E. G. Van Meir
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Neuro-oncol, April 1, 2005; 7(2): 134 - 153.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Mantha, J. E.L. Hanson, G. Goss, A. E. Lagarde, I. A. Lorimer, and J. Dimitroulakos
Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor
Clin. Cancer Res., March 15, 2005; 11(6): 2398 - 2407.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella, P. P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, et al.
EGFR Mutations in Non-Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
J. Clin. Oncol., February 1, 2005; 23(4): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood, January 1, 2005; 105(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Lammering, T. H. Hewit, M. Holmes, K. Valerie, W. Hawkins, P.-S. Lin, R. B. Mikkelsen, and R. K. Schmidt-Ullrich
Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity
Clin. Cancer Res., October 1, 2004; 10(19): 6732 - 6743.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. M. Sorscher, J. N. Rich, B.K. A. Rasheed, H. Yan, G. Rossi, A. Marchioni, L. Longo, D. A. Haber, D. W. Bell, and T. J. Lynch
EGFR Mutations and Sensitivity to Gefitinib
N. Engl. J. Med., September 16, 2004; 351(12): 1260 - 1261.
[Full Text] [PDF]

Home page
 NeurologyHome page
C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo
Genetically modified adenoviruses against gliomas: From bench to bedside
Neurology, August 10, 2004; 63(3): 418 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Vogt, S.-H. Lefevre, F. Apiou, A.-M. Dutrillaux, A. Cor, P. Leuraud, M.-F. Poupon, B. Dutrillaux, M. Debatisse, and B. Malfoy
Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas
PNAS, August 3, 2004; 101(31): 11368 - 11373.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. G. Johns, T. E. Adams, J. R. Cochran, N. E Hall, P. A. Hoyne, M. J. Olsen, Y.-S. Kim, J. Rothacker, E. C. Nice, F. Walker, et al.
Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor
J. Biol. Chem., July 16, 2004; 279(29): 30375 - 30384.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, et al.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
N. Engl. J. Med., May 20, 2004; 350(21): 2129 - 2139.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. A. Bhowmick, Z. Zhuang, S. D. Wait, and R. J. Weil
A Functional Polymorphism in the EGF Gene Is Found with Increased Frequency in Glioblastoma Multiforme Patients and Is Associated with More Aggressive Disease
Cancer Res., February 15, 2004; 64(4): 1220 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
C. L. Sawyers
Opportunities and challenges in the development of kinase inhibitor therapy for cancer
Genes & Dev., December 15, 2003; 17(24): 2998 - 3010.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Shinojima, K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. Makino, H. Saya, H. Hirano, J.-i. Kuratsu, et al.
Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme
Cancer Res., October 15, 2003; 63(20): 6962 - 6970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-H. Zhou, F. Tan, K. R. Hess, and W. K. A. Yung
The Expression of PAX6, PTEN, Vascular Endothelial Growth Factor, and Epidermal Growth Factor Receptor in Gliomas: Relationship to Tumor Grade and Survival
Clin. Cancer Res., August 1, 2003; 9(9): 3369 - 3375.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. A. Beebe, G. J. Wiepz, A. G. Guadarrama, P. J. Bertics, and T. J. Burke
A Carboxyl-terminal Mutation of the Epidermal Growth Factor Receptor Alters Tyrosine Kinase Activity and Substrate Specificity as Measured by a Fluorescence Polarization Assay
J. Biol. Chem., July 11, 2003; 278(29): 26810 - 26816.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. J. Brat and T. B. Mapstone
Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression
Ann Intern Med, April 15, 2003; 138(8): 659 - 668.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. Lavictoire, D. A. E. Parolin, A. C. Klimowicz, J. F. Kelly, and I. A. J. Lorimer
Interaction of Hsp90 with the Nascent Form of the Mutant Epidermal Growth Factor Receptor EGFRvIII
J. Biol. Chem., February 7, 2003; 278(7): 5292 - 5299.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. A. Jungbluth, E. Stockert, H. J. S. Huang, V. P. Collins, K. Coplan, K. Iversen, D. Kolb, T. J. Johns, A. M. Scott, W. J. Gullick, et al.
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
PNAS, January 21, 2003; 100(2): 639 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Eshleman, B. L. Carlson, A. C. Mladek, B. D. Kastner, K. L. Shide, and J. N. Sarkaria
Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy
Cancer Res., December 15, 2002; 62(24): 7291 - 7297.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Narita, M. Nagane, K. Mishima, H-J. S. Huang, F. B. Furnari, and W. K. Cavenee
Mutant Epidermal Growth Factor Receptor Signaling Down-Regulates p27 through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Glioblastomas
Cancer Res., November 15, 2002; 62(22): 6764 - 6769.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Rolf. F. Barth, W. Yang, D. M. Adams, J. H. Rotaru, S. Shukla, M. Sekido, W. Tjarks, R. A. Fenstermaker, M. Ciesielski, M. M. Nawrocky, et al.
Molecular Targeting of the Epidermal Growth Factor Receptor for Neutron Capture Therapy of Gliomas
Cancer Res., June 1, 2002; 62(11): 3159 - 3166.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, et al.
PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme
J Natl Cancer Inst, August 15, 2001; 93(16): 1246 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hidalgo, L. L. Siu, J. Nemunaitis, J. Rizzo, L. A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten, L. Denis, et al.
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
J. Clin. Oncol., July 1, 2001; 19(13): 3267 - 3279.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Sonoda, T. Ozawa, Y. Hirose, K. D. Aldape, M. McMahon, M. S. Berger, and R. O. Pieper
Formation of Intracranial Tumors by Genetically Modified Human Astrocytes Defines Four Pathways Critical in the Development of Human Anaplastic Astrocytoma
Cancer Res., July 1, 2001; 61(13): 4956 - 4960.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al.
The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux
Cancer Res., January 1, 2001; 61(2): 739 - 748.
[Abstract] [Full Text]

Home page
 Neuro OncolHome page
L. Frederick, G. Eley, X.-Y. Wang, and C. D. James
Analysis of genomic rearrangements associated with EGFRvIII expression suggests involvement of Alu repeat elements
Neuro-oncol, July 1, 2000; 2(3): 159 - 163.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Onlin